Mode
Text Size
Log in / Sign up

Metabolic syndrome associated with higher cardio-renal risk in kidney transplant recipientsMetabolic syndrome linked to higher risks for heart problems and kidney graft issues after transplant

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider metabolic syndrome as a risk marker for adverse cardio-renal outcomes in transplant recipients.

A systematic review and meta-analysis examined the association between metabolic syndrome and cardio-renal outcomes in 8,986 kidney transplant recipients (3,962 with metabolic syndrome, 5,024 without). The analysis compared outcomes between those with and without metabolic syndrome, though specific diagnostic criteria and follow-up duration were not reported.

The presence of metabolic syndrome was associated with significantly higher risks across multiple outcomes. For major adverse cardiovascular events, the relative risk was 2.12 (95% CI: 1.32 to 3.41, p = 0.002). All-cause mortality risk increased with a relative risk of 1.78 (95% CI: 1.21 to 2.62, p = 0.003). Graft failure showed a relative risk of 1.95 (95% CI: 1.58 to 2.39, p < 0.00001), and acute graft rejection had a relative risk of 1.53 (95% CI: 1.11 to 2.11, p = 0.009). Absolute event numbers were not reported.

Safety and tolerability data were not reported. Key limitations include the observational nature of the included studies and the need for large-scale prospective cohort studies using standardized metabolic syndrome definitions. The authors note this demonstrates association, not causation, and clinical management recommendations cannot be directly derived. The findings suggest metabolic syndrome may be an important risk marker in this population, but causal inference requires further study.

Researchers analyzed data from previous studies to understand how metabolic syndrome affects people who have received a kidney transplant. Metabolic syndrome is a group of health conditions that often occur together, including high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels. The review included information on nearly 9,000 transplant recipients, comparing those with metabolic syndrome to those without it.

The analysis found that transplant patients with metabolic syndrome had higher risks of several serious health problems. Their risk of major heart events was about twice as high. They also had higher risks of dying from any cause, losing their transplanted kidney (graft failure), and experiencing acute rejection where the body attacks the new kidney.

It's important to understand that this was a review of observational studies, which can show links but cannot prove that one thing causes another. The researchers noted that more large-scale studies are needed to confirm these findings and to use consistent definitions of metabolic syndrome. For now, this review highlights that metabolic syndrome is a significant marker of potential health risks for people living with a kidney transplant, but it does not provide specific new treatment recommendations.

What this means for you:
Metabolic syndrome is linked to higher risks for heart and kidney problems after transplant, but more research is needed.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Kidney transplant recipients (KTRs) are at elevated risk for metabolic syndrome (MS), primarily due to the side effects of immunosuppressive therapy. Emerging evidence suggests that MS may be associated with adverse outcomes such as cardiovascular disease (CVD), reduced graft function, and graft loss. This review aims to evaluate the association between MS and cardio-renal outcomes in KTRs, specifically its impact on the incidence of cardiovascular events, all-cause mortality, graft failure, and acute graft rejection. METHODS: We conducted a comprehensive search in MEDLINE, EMBASE, and CENTRAL databases from inception to August 2024. No language restrictions were applied. Two reviewers independently screened articles, extracted data, and assessed study quality. Meta-analyses were conducted using fixed-effect or random-effects models depending on heterogeneity. Effect estimates were reported as risk ratios (RRs) with 95% confidence intervals (CIs). RESULTS: Fifteen studies comprising a total of 8986 KTRs (3962 with MS and 5024 without MS) were included. Six studies reported major adverse cardiovascular events and all-cause mortality, nine studies reported graft failure, and seven studies reported acute graft rejection. KTRs with MS had higher risk for major adverse cardiovascular events (RR 2.12, 95% CI: 1.32 to 3.41, p = 0.002), all-cause mortality (RR 1.78, 95% CI: 1.21 to 2.62, p = 0.003), graft failure (RR 1.95, 95% CI 1.58 to 2.39, p < 0.00001) and acute graft rejection (RR 1.53, 95% CI 1.11 to 2.11, p = 0.009). CONCLUSION: KTRs with MS are at significantly increased risk of adverse cardiovascular and renal outcomes. Further large-scale prospective cohort studies using standardized definitions are needed to strengthen causal inference and guide clinical management in this population.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.